Form 4: Cadrenal Therapeutics Insider Sells Shares

Quang Pham, Chairman and CEO of Cadrenal Therapeutics, Inc., reported the sale of 7,400 shares of common stock under a Rule 10b5-1 trading plan.

Summary

• Quang Pham, Chairman and CEO of Cadrenal Therapeutics, Inc., has reported a transaction involving the sale of 7,400 shares of the company's common stock.
• The sale occurred on June 29, 2026, and was executed under a pre-arranged Rule 10b5-1 trading plan, adopted on September 25, 2025.
• The shares were sold at a weighted average price of $3.03, with individual transactions ranging from $3.00 to $3.13.
• Following this transaction, Mr. Pham directly beneficially owns 98,589 shares of common stock.
• Additionally, Mr. Pham is associated with 200,000 shares held indirectly through The PVBQ Living Trust, where he serves as Trustee and has sole voting and dispositive power. His child is the sole beneficiary of this trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the sale is conducted under a pre-established plan, mitigating concerns of opportunistic insider trading, but still represents a reduction in executive holdings.

Positives

• The sale was conducted under a Rule 10b5-1 trading plan, indicating a pre-determined and structured approach to stock sales, which can mitigate concerns about insider trading.
• Mr. Pham retains a significant direct beneficial ownership of 98,589 shares and indirect ownership through a trust, suggesting continued commitment to the company.

Negatives

• The sale represents a disposition of company stock by a key executive, which could be perceived negatively by the market.
• The total value of the shares sold is approximately $22,422 (7,400 shares * $3.03 average price).

Risks

• The sale of shares by a high-ranking executive, even under a 10b5-1 plan, could be interpreted as a lack of confidence in the company's immediate future prospects by some investors.
• Potential for further sales under the 10b5-1 plan, depending on its terms and market conditions.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. The Rule 10b5-1 plan suggests a structured approach to future potential sales, but specific volumes or timing are not disclosed.

Management Comments

• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider sales, particularly under Rule 10b5-1 plans, are common in the biotechnology and pharmaceutical sectors as executives manage personal finances while adhering to regulatory requirements. The specific price range of the sale may reflect current market valuations for companies at Cadrenal Therapeutics' stage.

Stakeholder Impact

• Shareholders: May view the sale with caution, although the Rule 10b5-1 plan provides some reassurance. The continued significant ownership by the executive should be noted.
• Employees: May interpret the sale based on their perception of the executive's confidence in the company's future.
• Creditors: Unlikely to be directly impacted by this specific transaction.

Next Steps

• Continued monitoring of insider transactions for any further sales or purchases.
• Review of future company announcements for performance updates that might influence insider trading behavior.

Key Dates

Keywords

Cadrenal Therapeutics, CVKD, Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Beneficial Ownership, Quang Pham, Chairman and CEO, SEC Filing